New biomarker for bowel cancer could help predict if disease will spread

Scientists have identified a protein that could play a crucial role in recognising whether bowel cancer patients need chemotherapy as there is a high risk of their bowel cancer spreading, according to a new study1 published in the British Journal of Cancer.

Scientists at the University of Southampton, part-funded by the Medical Research Council and Cancer Research UK, found that patients with low levels of the protein, known as FOXO32, had an increased risk of their cancer spreading to other parts of the body.

By comparing levels of FOXO3 in tissue samples from patients with different stages of the researchers found the protein was a good predictor of how aggressive a tumour is – decreasing levels of the protein were linked to more aggressive cancers.

Mr Marc Bullock, study author, MRC Clinical Research Training Fellow and bowel cancer surgeon at Southampton General Hospital, said: "Our findings suggest that looking at levels of FOXO3 could help single out which patients need extra treatment to help stop their cancer from coming back, as well as being a good potential target for drug development. Although other studies have looked at the role of FOXO3 in stopping tumours growing, this is the first time that such a clear link between levels of the and tumour growth has been identified."

Mr Alexander Mirnezami, co-author and bowel at Southampton General Hospital said: "As our research continues, we hope to identify lots of other new biomarkers that can help us adapt treatments based on individual patients' tumour characteristics as part of a personalised approach to ."

Dr Julie Sharp, senior science communications manager at Cancer Research UK, said: "This fascinating new finding could help doctors tackle the problem of bowel cancer spread. Although levels of FOXO3 alone are not enough to accurately predict whether a patient's cancer will return, the authors' highlight several other potential that, alongside FOXO3, could offer a powerful new tool to help doctors decide the best way to treat patients."

Related Stories

New type of bowel cancer discovered

Apr 15, 2013

(Medical Xpress)—A unique sub-type of bowel cancer has been discovered which has a worse outcome than other types of colon cancer and is resistant to certain targeted treatments, according to research published ...

Alternative target for breast cancer drugs

Jul 19, 2013

Scientists have identified higher levels of a receptor protein found on the surface of human breast tumour cells that may serve as a new drug target for the treatment of breast cancer. The results, which are published today ...

Recommended for you

Scientists discover hidden subpopulation of melanoma cells

56 minutes ago

UNC School of Medicine researchers have pinpointed a set of intriguing characteristics in a previously unknown subpopulation of melanoma cancer cells in blood vessels of tumors. These cells, which mimic non-cancerous ...

Blood biomarker may detect lung cancer

18 hours ago

A new study shows that patients with stage I to stage III non-small cell lung cancer have different metabolite profiles in their blood than those of patients who are at risk but do not have lung cancer. The study abstract ...

User comments